Investigational drug · Phase 2
TYPHIBEV
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Diarrhoea, Salmonella Infections.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
6
Any phase or sponsor naming "TYPHIBEV"
First trial start
2024
Nov 13, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TYPHIBEV", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diarrhoea
- Salmonella Infections
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "TYPHIBEV" as an intervention, largest first.
- Vellore Typhoid Vaccine Impact TrialPivotal-lookingCompleted
Christian Medical College, Vellore, IndiaAcademic, hospital or other
NCT05500482 · 72,400 participants · Start May 1, 2023 · Primary completion Jan 31, 2026
Drug: Typhoid conjugate Vaccine · For: Typhoid Fever
Sites: Vellore, India
- A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in InfantsPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07286370 · 537 participants (planned) · Start Apr 1, 2026 · Primary completion Apr 27, 2028
Drug: Low dose of iNTS-TCV; Full dose of iNTS-TCV and 2 more · For: Salmonella Infections
Sites: Banjul, The Gambia
- A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in InfantsPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT06663436 · 200 participants · Start Nov 13, 2024 · Primary completion Oct 21, 2025
Drug: altSonflex1-2-3 Dose A; altSonflex1-2-3 Dose B and 3 more · For: Diarrhoea
Sites: Kericho, Kenya
- A Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GSK Vaccines Institute for Global Health (GVGH) Quadrivalent Pan-Salmonella Vaccine With and Without Alum in Healthy Young AdultsPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07663032 · 196 participants (planned) · Start Jun 24, 2026 · Primary completion Nov 14, 2027
Drug: Pan-Salmonella-with-Alum (Low dose) vaccine; Pan-Salmonella-with-Alum (Full dose) vaccine and 3 more · For: Salmonella Infections
Sites: Bloemfontein, South Africa
- Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African ChildrenPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07320716 · 179 participants (planned) · Start Feb 6, 2026 · Primary completion Oct 16, 2028
Drug: AltSonflex1-2-3; Menveo and 2 more · For: Diarrhoea
Sites: Kericho, Kenya
Kathleen NeuzilAcademic, hospital or other
NCT07624175 · 147 participants · Start Aug 17, 2024 · Primary completion Oct 26, 2024
Drug: Vi capsular polysaccharide-CRM197 conjugate vaccine (Vi-CRM), 0.5 mL IM · For: Typhoid
Sites: Ouagadougou, Burkina Faso
Newest research
PubMed records naming it or its code names, newest first.
- Integrating environmental and clinical surveillance for typhoid: insights from a prospective wastewater surveillance study in urban India.
Mohan VR, Abraham D, John J, et al. · Lancet Microbe 2026
- Effectiveness of the TYPHIBEV® (Vi-CRM197 conjugate) vaccine introduction in Nepal: A test-negative, case-control study.
Tamrakar D, Shahi SB, Jung E, et al. · J Infect 2026
- Real-world vaccine effectiveness of typhoid conjugate vaccine in children and adolescents: a systematic review and meta-analysis.
Haposan JH, Icanervilia AV, Watts E, et al. · Vaccine 2025
- GMMA-based vaccine candidates against invasive nontyphoidal salmonellosis elicit bactericidal antibodies against a panel of epidemiologically relevant Salmonellae.
De Simone D, Pinto M, Aruta MG, et al. · Front Immunol 2025
- Safety and immunogenicity of Biological E's typhoid conjugate vaccine TYPHIBEVⓇ concomitantly administered with measles rubella vaccine: a phase IV prospective, multicenter study.
Thuluva S, Matur RV, Gunneri S, et al. · IJID Reg 2025
- An observer-blinded, cluster randomised trial of a typhoid conjugate vaccine in an urban South Indian cohort.
Sahai N, Arunachalam DK, Morris T, et al. · Trials 2023
Also in development for Diarrhoea
- DTap-HepB-IPV-Hib vaccineHexyon, Infanrix hexaPhase 34 trials
Sanofi · Healthy Volunteers, Meningococcal Immunization, Pneumococcal Immunization
- AltSonflex1-2-3Phase 23 trials
GSK · Diarrhoea
- MR-VACPhase 22 trials
GSK · Diarrhoea
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.